You are here

Article info

Article menu
Download PDFPDF
Original research
Analysis of FDA’s IQOS marketing authorisation and its policy impacts

Authors

  1. Correspondence to Professor Stanton Glantz, Center for Tobacco Control Research and Education, University of California, San Francisco CA 94143, California, USA; Stanton.Glantz{at}ucsf.edu
View Full Text

Citation

Lempert LK, Glantz S
Analysis of FDA’s IQOS marketing authorisation and its policy impacts
Tobacco Control 2021;30:413-421.

Publication history

  • Received December 21, 2019
  • Revised April 29, 2020
  • Accepted May 5, 2020
  • First published June 29, 2020.
Online issue publication 
June 27, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.